Beyond its diagnostic and prognostic relevance, the inhibitory effect of CD109 on TGF-β signaling could mitigate tumor-promoting immunosuppression, restrain M2-like macrophage polarization, and restore T cell activity, thereby potentially enhancing anti-tumor immunity. This evidence concerns the gene TGFB1 and neoplasm.